Onconomics Plus: Test for an Integrative Cancer Treatment

Finding the most effective chemotherapy and natural substances

The Onconomics Plus test supports personalized cancer treatment planning by identifying which chemotherapy drugs, targeted therapies, and natural supplements work best against each patient’s unique cancer cells.

This test aims to support the combination of conventional tumor treatments with complementary therapies, such as the use of natural compounds, to support an integrative cancer treatment approach.

The Onconomics Plus test from RGCC also provides valuable insights into how the patient’s cancer cells respond to hyperthermia and radiation therapy, combining this data with genetic information for a truly comprehensive and integrative oncology approach.

By combining conventional treatments with natural agents, the test helps create a well-rounded, personalized treatment strategy that targets tumor cells, including cancer stem cells, and mitigates the spread of the disease.

Onconomics Plus provides a comprehensive overview of the cancer cells in a patient’s body by providing the following information:

• A Circulating Tumor Cell (CTC) count
• A genetic and physiological expression profile of the cancer cells
• The effectiveness of 90+ chemotherapeutic agents and targeted therapies on the patient’s cancer cells
• The effectiveness of 50+ natural substances on the patient’s cancer cells

The Onconomics Plus cancer blood test is based on the liquid biopsy technology and is used to develop individualized, evidence-based tumor treatments while advancing innovation in precision oncology.

How does Onconomics Plus work?

Onconomics Plus not only evaluates how effectively conventional anti-cancer drugs destroy tumor cells, but also assesses tumor sensitivity to natural substances, revealing which natural extracts may help inhibit cancer cell growth.

During the test, a blood or tissue sample is analyzed to test how effective specific therapies and treatments are at suppressing cancer. Through a combination of three assessments, the test evaluates the chemosensitivity of anti-cancer drugs, natural substances, in addition to the gene-expression profile of the cells.

The results categorize the effectiveness of each agent as follows:

• No sensitivity
• Partial sensitivity
• High sensitivity

To evaluate the effectiveness of only natural substances OR anti-cancer drugs, learn more about the RGCC Onconomics Panel, which also includes:

• the Onconomics Extracts test
• the Onconomics Extracts + test
• or the Ononomics test

Who should get an Onconomics Plus test?

Onconomics Plus is a valuable tool for cancer patients seeking a comprehensive overview of the most effective chemotherapy drugs, along with potential natural supplements tailored to target their unique cancer cells, recognizing that cancer cells do not always behave the same way.

It serves as a holistic guide for physicians, helping to identify the most effective conventional and integrative cancer treatment options. This is especially crucial when second or third-line treatments have failed to produce effective results.

The Onconomics Plus test is typically conducted following an Oncotrace test, which functions as an initial baseline evaluation for patients receiving cancer treatment. Oncotrace assists in assessing cancer progression and supports the evaluation of treatment effectiveness when conducted both before and after therapy.